D
David Spiegel
Researcher at Stanford University
Publications - 838
Citations - 50967
David Spiegel is an academic researcher from Stanford University. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 106, co-authored 733 publications receiving 46276 citations. Previous affiliations of David Spiegel include Tel Aviv University & University of Adelaide.
Papers
More filters
Journal ArticleDOI
Serotonin transporter polymorphism, depressive symptoms, and emotional impulsivity among advanced breast cancer patients
Youngmee Kim,Youngmee Kim,Charles S. Carver,Charles S. Carver,Joachim Hallmayer,Jamie M. Zeitzer,Oxana Palesh,Eric Neri,Bita Nouriani,David Spiegel +9 more
TL;DR: Findings provide the first evidence that low serotonergic function contributes to both depression and impulsivity within a clinically meaningful sample and suggest that depressive symptoms, particularly perceived interpersonal rejection, may be a pathway linking genotype to emotional impulsivity.
Journal ArticleDOI
Evening salivary cortisol as a single stress marker in women with metastatic breast cancer.
TL;DR: In this article, the authors examined which points in the diurnal curve are predictive of the slope of the curve and whether elevated evening cortisol levels alone are associated with reduced HPA-axis feedback inhibition (i.e., decreased sensitivity to the dexamethasone suppression test).
Journal ArticleDOI
Outcomes After Surgical Fixation of Posterior Sternoclavicular Physeal Fractures and Dislocations in Children.
Ishaan Swarup,Alejandro Cazzulino,Brendan A. Williams,Christopher J. DeFrancesco,David Spiegel,Apurva S. Shah +5 more
TL;DR: There is a paucity of literature on functional outcomes after surgical management of pediatric acute posterior SCFD, and Functional outcomes after surgery were satisfactory in this cohort with most patients being able to perform major activities of daily living.
Abstract CT030: Genomic and pathologic determinants of response to RP-3500, an ataxia telangiectasia and Rad3-related inhibitor (ATRi), in patients (pts) with DNA damage repair (DDR) loss-of-function (LOF) mutant tumors in the Phase 1/2 TRESR trial
Timothy A. Yap,Ian M. Silverman,Elisa Fontana,Elizabeth K. Lee,David Spiegel,Martin Højgaard,Stephanie Lheureux,Niharika B. Mettu,Benedito A. Carneiro,Louise Carter,Ruth Plummer,Joseph D. Schonhoft,Danielle B. Ulanet,Parham Eslami-Nejad,P. Manley,Jorge S. Reis-Filho,Yi Xu,Victoria Rimkunas,M. Koehler,Ezra Y. Rosen +19 more
TL;DR: RP-3500 has clinical activity across STEP2 genotypes including those pretreated with PARPi and with BRCA1 reversions including thosepretreated with Par Pi and with PSA or CA125 response.
Posted ContentDOI
Multi-site Validation of a SARS-CoV-2 IgG/IgM Rapid Antibody Detection Kit
Christopher Minteer,Arnau Casanovas-Massana,Tao Li,David A. McDonald,Linda Wang,Si Hui Pan,David Caianiello,Jesse Collinski,Edward deRamon,Robert Hale,Rebecca Howell,Jason Ray,Joseph M. Vinetz,Morgan E. Levine,Albert I. Ko,David Spiegel +15 more
TL;DR: The utility of a newly-designed lateral flow immunoassay (LFA) for detecting SARS-CoV-2 IgM and IgG antibodies is supported and a visual intensity reporting system that will provide granular information about antibody levels is developed.